Agios Pharmaceuticals IncNASDAQ:AGIO
- LAST PRICE44.1900
- TODAY'S CHANGE (%)-0.6400 (-1.4276%)
- Bid / Lots44.1400/ 8
- Ask / Lots44.2500/ 8
- Open / Previous Close44.5400 / 44.8300
- Day Range
- 52 Week Range
- Volume107,518
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AGIO |
|---|---|---|
| 09:32 ET | 3092 | 44.43 |
| 09:33 ET | 100 | 44.51 |
| 09:35 ET | 200 | 44.585 |
| 09:37 ET | 200 | 44.21 |
| 09:39 ET | 600 | 44.41 |
| 09:42 ET | 1100 | 44.405 |
| 09:44 ET | 100 | 44.3 |
| 09:46 ET | 200 | 44.57 |
| 09:48 ET | 300 | 44.26 |
| 09:51 ET | 9975 | 44.47 |
| 09:53 ET | 957 | 44.62 |
| 09:55 ET | 400 | 44.15 |
| 09:57 ET | 100 | 44.06 |
| 10:00 ET | 200 | 44.07 |
| 10:02 ET | 1100 | 43.9 |
| 10:06 ET | 1500 | 43.995 |
| 10:08 ET | 1750 | 44.04 |
| 10:09 ET | 300 | 44.15 |
| 10:11 ET | 2520 | 43.97 |
| 10:13 ET | 800 | 43.78 |
| 10:15 ET | 631 | 43.88 |
| 10:18 ET | 1387 | 43.71 |
| 10:20 ET | 600 | 43.76 |
| 10:22 ET | 200 | 43.76 |
| 10:24 ET | 100 | 43.63 |
| 10:26 ET | 1049 | 43.505 |
| 10:27 ET | 100 | 43.4 |
| 10:29 ET | 400 | 43.33 |
| 10:31 ET | 1080 | 43.29 |
| 10:33 ET | 448 | 43.26 |
| 10:36 ET | 1100 | 43.43 |
| 10:38 ET | 100 | 43.46 |
| 10:40 ET | 1110 | 43.46 |
| 10:42 ET | 900 | 43.64 |
| 10:44 ET | 525 | 43.65 |
| 10:45 ET | 611 | 43.775 |
| 10:47 ET | 200 | 43.92 |
| 10:49 ET | 500 | 43.97 |
| 10:51 ET | 200 | 43.985 |
| 10:54 ET | 1000 | 43.97 |
| 10:56 ET | 500 | 44.15 |
| 10:58 ET | 323 | 44.075 |
| 11:00 ET | 920 | 44.11 |
| 11:02 ET | 200 | 44.13 |
| 11:03 ET | 745 | 44.07 |
| 11:05 ET | 1230 | 44.07 |
| 11:07 ET | 658 | 44.16 |
| 11:09 ET | 200 | 44.18 |
| 11:12 ET | 930 | 44.105 |
| 11:14 ET | 100 | 44.09 |
| 11:16 ET | 3768 | 44.11 |
| 11:18 ET | 1400 | 44.11 |
| 11:20 ET | 500 | 44.16 |
| 11:21 ET | 800 | 44.12 |
| 11:23 ET | 400 | 44.07 |
| 11:27 ET | 200 | 44.17 |
| 11:30 ET | 300 | 44.16 |
| 11:32 ET | 500 | 44.15 |
| 11:34 ET | 300 | 44.18 |
| 11:36 ET | 400 | 44.25 |
| 11:38 ET | 900 | 44.31 |
| 11:39 ET | 805 | 44.3 |
| 11:41 ET | 100 | 44.32 |
| 11:43 ET | 400 | 44.24 |
| 11:45 ET | 100 | 44.33 |
| 11:48 ET | 300 | 44.26 |
| 11:50 ET | 1305 | 44.13 |
| 11:52 ET | 100 | 44.05 |
| 11:54 ET | 100 | 44.03 |
| 11:56 ET | 800 | 44.19 |
| 11:57 ET | 300 | 44.16 |
| 11:59 ET | 500 | 44.16 |
| 12:01 ET | 600 | 44.12 |
| 12:03 ET | 100 | 44.1 |
| 12:08 ET | 648 | 44.139 |
| 12:10 ET | 200 | 44.13 |
| 12:12 ET | 300 | 44.07 |
| 12:14 ET | 400 | 44.02 |
| 12:15 ET | 400 | 44.07 |
| 12:17 ET | 301 | 44.14 |
| 12:19 ET | 100 | 44.19 |
Today
Nov 1, 2024
DJ Agios Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 12:43PM ET on Friday Nov 01, 2024 by Dow Jones
12:43PM ET on Friday Nov 01, 2024 by Dow JonesDJ Agios Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank, from 10:30AM ET on Friday Nov 01, 2024 by Dow Jones
10:30AM ET on Friday Nov 01, 2024 by Dow Jones
Oct 31, 2024
*DJ Agios Pharmaceuticals 3Q EPS $16.22 >AGIO, from 6:30AM ET on Thursday Oct 31, 2024 by Dow Jones
6:30AM ET on Thursday Oct 31, 2024 by Dow JonesAgios Reports Business Highlights and Third Quarter 2024 Financial Results, from 6:30AM ET on Thursday Oct 31, 2024 by Dow Jones
6:30AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Agios Pharmaceuticals Inc | 2.6B | 3.6x | --- |
IDEAYA Biosciences Inc | 2.5B | -12.5x | --- |
Geron Corp | 2.6B | -11.8x | --- |
Scholar Rock Holding Corp | 2.5B | -12.4x | --- |
CG Oncology Inc | 2.5B | -30.8x | --- |
SpringWorks Therapeutics Inc | 2.3B | -7.0x | --- |
Company Information
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Contact Information
- Headquarters
- 88 Sidney StreetCAMBRIDGE, MA, United States 02139
- Phone
- 617-649-8600
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Jacqualyn Fouse
- Chief Executive Officer, Director
- Brian Goff
- Chief Financial Officer
- Cecilia Jones
- Chief Legal Officer
- James Burns
- Chief Medical Officer, Head - Research and Development
- Sarah Gheuens
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6B |
|---|---|
Revenue (TTM) | $32.9M |
Shares Outstanding | 57.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.71 |
EPS | $12.28 |
Book Value | $14.50 |
P/E Ratio | 3.6x |
Price/Sales (TTM) | 77.8 |
Price/Cash Flow (TTM) | 3.5x |
Operating Margin | 2,075.26% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
